Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +14

<i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Laurent Hennequin, J M Allen, J. Breed et al. · Journal of Medicinal Chemistry · 2006 · 367 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery

Edward H. Kerns, Li Di, Susan Petusky et al. · Journal of Pharmaceutical Sciences · 2004 · 270 citations

Natural Sciences, Biophysics, Pharmacology +15

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Stuart Cockerill, Colin Stubberfield, Jeremy N. Stables et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 80 citations · Full text

Medicine, Medicinal Chemistry, Oncology +9

Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

Tai W. Wong, Francis Y. Lee, Chiang Yu et al. · Clinical Cancer Research · 2006 · 79 citations

Medicine, Medicinal Chemistry, Oncology +13